Cyclophosphamide to Reduce Complications Following Haploidentical Stem Cell Transplantation
If non-Hodgkin lymphoma (NHL) cannot be controlled with standard therapy (refractory), a stem cell transplant from a compatible donor may be recommended. In a so-called haploidentical stem cell transplant, the immunological similarity between the donor and the recipient is lower, and rejection reactions may occur as a complication of the transplant. This risk could potentially be reduced by administering a high dose of the drug cyclophosphamide. The aim of the study is to investigate whether high-dose cyclophosphamide administered after a haploidentical stem cell transplant can prolong disease-free survival and reduce the risk of rejection reactions. Women and men aged 18–65 with relapsed or refractory NHL who are receiving a haploidentical allogeneic stem cell transplant are eligible to participate in this study.
18–65 years · Relapsed / refractory · Phase II